This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Yano, J. Articles by Irimura, T. Search for Related Content PubMed PubMed Citation Articles by Yano, J. Articles by Irimura, T.

Antitumor Activity of Small Interfering RNA/Cationic Liposome Complex in Mouse Models of Cancer

¹ Discovery Research Laboratories, Nippon Shinyaku Co, Ltd., Kyoto, Japan; and ² Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo, Japan

Purpose: The RNA interference effect is an alternative to antisense DNA as an experimental method of down-regulating a specific target protein. Although the RNA interference effect, which is mediated by small interfering RNA (siRNA) or micro-RNA, has potential application to human therapy, the hydrodynamic method usually used for rapid administration of oligonucleotides is unsuitable for use in humans. In this study, we have investigated the antitumor activity of a synthetic siRNA, B717, which is sequence specific for the human bcl-2 oncogene, complexed with a novel cationic liposome, LIC-101.

Experimental Design: In a mouse model of liver metastasis, we administered B717/LIC-101 by bolus intravenous injection, adjusting the rate and volume of administration to what is feasible in human therapy. In a mouse model bearing prostate cancer in which the cells were inoculated under the skin, B717/LIC-101 was administered subcutaneously around the tumor.

Results: The B717/LIC-101 complex inhibited the expression of bcl-2 protein and the growth of tumor cell lines in vitro in a sequence-specific manner in the concentration range of 3 to 100 nmol/L. Furthermore, the complex had a strong antitumor activity when administered intravenously in the mouse model of liver metastasis. B717 (siRNA) was shown to be delivered to tumor cells in the mouse liver, but only when complexed with LIC-101. The complex also inhibited tumor cell growth in the mouse model bearing prostate cancer.

Conclusions: By combining siRNA with our cationic liposome, we overcame the difficulty of administering siRNA to animals in ways that can be applied in human therapy. Although our siRNA/liposome complex is not yet in clinical trials, it is expected to provide a novel siRNA therapy for cancer patients.

This article has been cited by other articles:

				E. Ashihara, E. Kawata, Y. Nakagawa, C. Shimazaski, J. Kuroda, K. Taniguchi, H. Uchiyama, R. Tanaka, A. Yokota, M. Takeuchi, et al. {beta}-Catenin Small Interfering RNA Successfully Suppressed Progression of Multiple Myeloma in a Mouse Model Clin. Cancer Res., April 15, 2009; 15(8): 2731 - 2738. [Abstract] [Full Text] [PDF]

				T. Abe, K. Goda, K. Futami, and Y. Furuichi Detection of siRNA administered to cells and animals by using a fluorescence intensity distribution analysis polarization system Nucleic Acids Res., April 1, 2009; 37(7): e56 - e56. [Abstract] [Full Text] [PDF]

				S. Sonoke, T. Ueda, K. Fujiwara, Y. Sato, K. Takagaki, K. Hirabayashi, T. Ohgi, and J. Yano Tumor Regression in Mice by Delivery of Bcl-2 Small Interfering RNA with Pegylated Cationic Liposomes Cancer Res., November 1, 2008; 68(21): 8843 - 8851. [Abstract] [Full Text] [PDF]

				E. Kawata, E. Ashihara, S. Kimura, K. Takenaka, K. Sato, R. Tanaka, A. Yokota, Y. Kamitsuji, M. Takeuchi, J. Kuroda, et al. Administration of PLK-1 small interfering RNA with atelocollagen prevents the growth of liver metastases of lung cancer Mol. Cancer Ther., September 1, 2008; 7(9): 2904 - 2912. [Abstract] [Full Text] [PDF]

				O. R. Mook, F. Baas, M. B. de Wissel, and K. Fluiter Evaluation of locked nucleic acid-modified small interfering RNA in vitro and in vivo Mol. Cancer Ther., March 1, 2007; 6(3): 833 - 843. [Abstract] [Full Text] [PDF]

				T. Katoh and T. Suzuki Specific residues at every third position of siRNA shape its efficient RNAi activity Nucleic Acids Res., February 28, 2007; 35(4): e27 - e27. [Abstract] [Full Text] [PDF]